Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective?

Similar documents
Disclosure (s) Relevant financial relationship(s) None Off-label usage None Change in slide set You betcha! (YES!) 2015 MFMER slide-1

Coagulation Cascade. TF-VIIa. Tissue Factor + VII. XIIa. Prothrombin. XIa. IXa. VIIIa. Thrombin. XL- Fibrin. XIII Monomer. Fibrinogen.

Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues

Hypercoagulation. CP Conference 11/14/2006

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:

TSOAC Case Study 1. Question. TSOAC Case Study 1 Continued

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

4/5/2017. Molecular Testing Applications in Coagulation. Disclosures. Objectives. Human Genome Chromosome Analysis.

Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.

Principles of Coagulation Testing. Andy Nguyen, MD 8/4/2010

Virtual Lectures Planning Committee Disclosure Summary

Sysmex Educational Enhancement and Development No

SEED Coagulation. Sysmex Educational Enhancement and Development April 2014

Haemostasis Reagents product list 2018

DOAC s and Implications on Laboratory Results. Kandice Kottke-Marchant, MD, PhD Cleveland Clinic

Coagulation. Coagulation Limited CGL, CGDF Surveys & Anatomic Pathology Education Programs. Coagulation 117

Coagulopathy Case-2. Andy Nguyen, M.D. 2009

Clumsy Coagulation Communication

Laboratory Testing Issues for Protein C, Protein S and Antithrombin Assays

Evaluation of Unexplained Prolonged APTT &/or PT Review & Update

Phoenix, AZ Laboratory - Test Menu

Phoenix, Arizona, Laboratory Test Menu

Laboratory Aspects of recombinant porcine FVIII and extended half life concentrates

Evaluation of the Bleeding Patient

Phoenix, AZ Laboratory - Test Menu

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

2 Thomas G. DeLoughery

S1865 Coagulation Testing: How Do We Get the Best Results?

Automated Coagulation Analyser product list 2018

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

PROTHROMBIN TIME WHY USE LOW ISI (HIGH SENSITIVITY)

Diagnosing Haemostasis PRODUCT CATALOG

Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors

Pearls and Pitfalls in Factor Inhibitor Testing

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

Laboratory Monitoring of Unfractionated Heparin Therapy

Primary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system

Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc All rights reserved.

Type of intervention Treatment; secondary prevention. Economic study type Cost-effectiveness analysis.

DOACs: When and how to measure their anticoagulant effect

Laboratory Monitoring of Anticoagulation

The Coagulation Workup In The Office Setting

ANTITHROMBIN FACTOR Xa

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016

Upon completion of the Clinical Hematology rotation, the MLS student will be able to:

UK NEQAS FOR BLOOD COAGULATION: Programmi EQAS nel laboratorio di coagulazione

LABORATORY APPROCH TO THE BLEEDING PATIENT

CoaDATA product list valid from

FACTOR V of LEIDEN REAL TIME

Clinical Implications Of Apc-Resistance And Factor 5 Leiden Mutational Testing Over A Five Year Period At Yale-New Haven Hospital

Basic coagulation applications and case studies

General Principles of. Hemostasis. Kristine Krafts, M.D.

Linking in silico and in vitro experiments to identify and evaluate a biomarker for enoxaparin activity

Laboratory Diagnosis of the Lupus Anticoagulant

Sensitivity and Specificity ofthe APC Resistance Assay in Detection of Individuals With Factor V Leiden

Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017

Use of Chromogenic Assay of Factor X to Accept or Reject INR Results in Warfarin Treated Patients

WFH 2014 World Congress Medical Free Paper 8 ALN AT3: An Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK

CE Update. Pre-analytical Variables in Coagulation Testing Associated With Diagnostic Errors in Hemostasis

Comparison of Russell Viper Venom Based and Activated Partial Thromboplastin Time Based Screening Assays for Resistance to Activated Protein C

Residual Serum Thrombin

Note: The taller 100 x 13 mm tube is not designed to run on the ACL TOP. Plasma after centrifugation of these tubes must be placed in sample cups.

R.Li, C.Swaelens, F.Vandermijnsbrugge, B.Cantinieaux BSTH Laboratory of haematology, Porte de Hal,

Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1

QUALITY PROGRAMME MANUAL 2013

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications

Customer Service. For further product information, technical advice, prices or to place an order contact. Phone:

Coagulation Mechanisms Dr. Nervana Bayoumy

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO

Hemostasis practice: state-of-the-art

QUALITY PROGRAMME MANUAL 2014

Acute Traumatic Coagulopathy

2009 LAP Audioconference Series. Simple Tests, Tough Problems Patient Care and Laboratory Inspection in Coagulation

Ch 13: Blood. What does blood do? Transport: Regulation: Protection:

Critical aspects in routine coagulation testing

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

Establishing a Saudi Arabian Reference Range for Physiological. anticoagulants Antithrombin III Protein C, Protein S and Resistance

NEW INITIATIVES. Factor XIII, Fibrinolysis, Heparin. Piet Meijer. ECAT Foundation. Leiden The Netherlands

Novel Anti-coagulant Agents. David G Hovord BA MB BChir FRCA Clinical Assistant Professor University of Michigan

These slides and the data they contain are the sole property of the author(s) of the slide set.

ROTEM Basic Interpretation Guide

73 Coagulation Laboratory: Methods, Standards and Cost Effective Testing (Part 1) Donna Castellone MS, MT(ASCP)SH

Stability of Plasma for Add-On PT and APTT Tests

Effect of Direct Thrombin Inhibitors, Bivalirudin, Lepirudin, and Argatroban, on Prothrombin Time and INR Values

Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

EDUCATIONAL COMMENTARY D-DIMER UPDATE

ECAT FOUNDATION. External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

With Stago, discover an outstanding Routine range

Lina Al-Lawama. Rama Al-Ashqar. Malik Al-Zohlof

The Comprehensive and Efficient Solution. for Your Hemostasis Lab. Hemostasis System

CHROMOGENIC SUBSTRATE TECHNOLOGY. Giovanni Russi

Using TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS

Newsletter from All Eights

Coagulation in perspective: Blood management. Objectives

Schedule of Accreditation

Transcription:

Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective? Rajiv K. Pruthi, M.B.B.S Co-Director, Special Coagulation Laboratory & Director, Mayo Comprehensive Hemophilia Center Division of Hematology/Internal Medicine Dept of Laboratory Medicine & Pathology Mayo Clinic, Rochester, MN 2017 MFMER slide-1

Multifactorial Disease Acquired + inherited Acquired Inherited Thrombosis Acquired + acquired Inherited + inherited 2017 MFMER slide-2

Thrombophilia Profile: Reflexive Testing Approach THRMP/Thrombophilia Profile Testing begins with Prothrombin Time (PT), Plasma Activated Partial Thromboplastin Time (APTT), Plasma Dilute Russells Viper Venom Time (DRVVT), Plasma Thrombin Time (Bovine), Plasma Fibrinogen, Plasma D-Dimer, Plasma Soluble Fibrin Monomer Antithrombin Activity, Plasma Protein C Activity, Plasma Protein S Antigen, Free, Plasma Prothrombin G20210A A Mutation, Blood Activated Protein C Resistance V (APCRV), Plasma Special Coagulation Interpretation PT: 14.0 seconds APTT: >36 seconds DRVVT: 1.2 seconds Thrombin Time (Bovine) APCRV: <2.3 OR PT Mix 1:1 APTT Mix 1:1 DRVVT Mix 1:1 Prolonged baseline APTT 15-23 sec >23 sec Protein C Activity: <70% Protein S. Antigen, Free Males <65% Females <50 years: <50% 50 years: <65% Antithrombin Activity: <80% No evidence of an acquired deficiency 14.0 <14.0 36 >36 1.2 <1.2 Evidence of inhibition* Evidence of coagulation factor deficiency* Evidence of inhibition* Evidence of coagulation factor deficiency* Normal no evidence of heparin or dys/ hypofibrinogenemia Reptilase Time Factor V Leiden (R506Q) Mutation Protein C Antigen Protein S Antigen, Total Antithrombin Antigen, Plasma All initial testing within reference ranges for age and gender: No evidence of thrombotic diathesis No further testing is performed Possible factor inhibitor* No evidence of heparin in sample Does not shorten Platelet neutralization procedure (PNP) Shortens by 4-5 seconds Evidence of lupuslike anticoagulant DRVVT Confirmation 1.2 <1.2 Anticoagulant effect ** No diagnostic of lupuslike anticoagulant 14-23 sec >23 sec Possible dys/ hypofibrinogenemia* *Additional assays may be performed if further clarification or confirmation is necessary. These may include: Coagulation Factor Assays Staclot Lupus Anticoagulant Protein S Activity **Unfractionated/low-molecular weight heparin or direct thrombin inhibitor (eg, dabigatran, argatroban) An interpretive report is provided that includes all profile tests (always performed) and any reflex tests performed (if appropriate). 2017 MFMER slide-3

Activated Protein C Resistance and Factor V Leiden Most common congenital hereditary thrombophilia among whites Protein phenotype Normally: Activated protein C (APC) inactivates activated factor V (fva) APC resistance: Mutated factor V resists inactivation by APC Genetic basis Factor V Leiden (R506Q) mutation Testing strategy Initial APC-R assay, FV Leiden only if indicated 2017 MFMER slide-4

APC Resistance assay: Normal Baseline aptt (30 sec) aptt after addition of APC (inactivates factor V, prolongs aptt) (90 sec) APCR ratio APC aptt (90) aptt (30) = 3.0 2017 MFMER slide-5

APC Resistance assay: Abnormal (FV Leiden) Baseline aptt (30 sec) aptt after addition of APC (inactivates factor V, prolongs aptt, but not as much as normal) (60 sec) APCR ratio APC aptt (60) aptt (30) = 2.0 V Leiden 2017 MFMER slide-6

Factor V Leiden Genetic Basis for activated protein C resistance Direct mutation analysis for presence or absence of FV Leiden Multiple different assay types 2017 MFMER slide-7

Approach to testing Screening test first Must be low cost yet requires high sensitivity (Risk false positive) DNA based test first Likely more expensive Low false positive/negative 2017 MFMER slide-8

Testing Strategy for APC-R and FV Leiden Taylor et al: Am J Clin Pathol 129:494, 2008 Taylor LJ et al Am J Clin Pathol 2008; 129: 494 2017 MFMER slide-9

Testing Strategy for APC-R and FV Leiden Taylor et al: Am J Clin Pathol 129:494, 2008 Taylor LJ et al Am J Clin Pathol 2008; 129: 494 2017 MFMER slide-10

Mayo Clinic, Rochester experience vs Optum labs Optum labs data warehouse >100 million enrollees Medical claims data for laboratory testing etc Inpatient and outpatient 2017 MFMER slide-11

Mayo APCR/FV Leiden vs Optum Labs database Test description Mayo Sp Coag Lab Optum Labs APC-R 1256 5,395 FV Leiden 268 80,129 Ratio: APCR:FVL Cost per evaluated individual (78,525) ~1: 0.2 ~1:15 $36.38 (savings: $47.39) $83.77 2011 Mayo Foundation for Medical Education and Research. All Rights Reserved. 2017 MFMER slide-12

Conclusion Screening with APC Resistance assay Reflexive FV Leiden confirmatory: More cost effective 2017 MFMER slide-13

Questions & Discussion 2017 MFMER slide-14